Alivus Life Sciences reported its highest-ever quarterly margins in Q3 FY’26, with revenue reaching Rs. 673 crores, a 4.8% YoY increase. EBITDA margin soared to 36.4%, up 510 bps YoY, driven by new product launches, favorable product mix, and operational efficiencies. The CDMO segment showed strong recovery, with revenue growth of 100% QoQ. The company expects high single-digit revenue growth for FY’26 and maintains a margin guidance of 30%-32%.
Financial Performance Highlights
Alivus Life Sciences announced revenue of Rs. 673 crores for Q3 FY’26, representing a growth of 14.4% QoQ and 4.8% YoY. This marks the company’s highest ever revenue. Non-GPL business grew by 16.1%. For the 9-month period, revenue stood at Rs. 1,863 crores, a 7.2% increase.
Profitability and Margins
The gross margin for the quarter was 58.9%, a 330 bps YoY increase. EBITDA margin reached 36.4%, up 510 bps YoY, which is the highest ever reported. PAT for the quarter was Rs. 150 crores. EBITDA for the 9-month period was Rs. 620 crores, a 22% increase, and PAT was Rs. 402 crores.
Segment Performance
The CDMO segment saw a strong recovery, delivering exceptional performance with revenue growth of 100% QoQ and 85.3% YoY. CVS and CNS therapies led the growth, contributing 51% to the topline.
Strategic Developments
The company’s pipeline remains robust with 595 DMF and CEP filings globally as of December 31st, 2025. The high potent API portfolio includes 27 products in the active grid. The company now guides FY’26 CAPEX to be around Rs. 450 crores compared to the earlier guidance of Rs. 600 crores.
Future Outlook
Alivus Life Sciences expects high single-digit revenue growth for FY’26, driven by expansion across its diversified non-GPL segment and continued ramp-up of CDMO projects. The company is confident in maintaining healthy margins, expected to range between 30%-32% going forward.
Source: BSE
